Medjeduse

Medjeduse is a pioneering company in the medical device sector, focusing on the development of innovative solutions for spinal cord injuries (SCI). The company operates in the healthcare and medical technology market, serving patients who have suffered traumatic central nervous system (CNS) injuries. Medjeduse's core product is a bioscaffold medical device designed to improve the repair of spinal cord injuries, thereby enhancing the restoration of locomotion and sensation. The device utilizes a neurosurgical liquid implant to preserve spared tissue and maximize tissue repair, pushing functional recovery beyond the current limits of rehabilitation. The business model revolves around the commercialization of this patented technology, which includes a degradable injectable Chitosan microgel with multiple biomedical applications such as drug formulation and wound healing. Medjeduse generates revenue through the sale of its medical devices and related technologies, targeting hospitals, rehabilitation centers, and medical professionals specializing in neurosurgery and spinal cord injuries. The company holds two key patents: one for the Chitosan microgel formulation and another for the method ensuring microgel quality.

Keywords: spinal cord injury, bioscaffold, neurosurgical implant, Chitosan microgel, locomotion restoration, sensation recovery, CNS injury, medical device, tissue repair, biomedical applications.